

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Chin-Ming Chang *et. al.*

Serial No: Not yet assigned

Filed: Herewith

For: COMBINATION OF BRIMONIDINE AND
TIMOLOL FOR TOPICAL OPHTHALMIC USE

Examiner: Not yet assigned

(Parent Case Art Unit: 1614

Parent Examiner: B. Kwon)

INFORMATION DISCLOSURE STATEMENTMail Stop: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22310-1450

Dear Sir:

Applicants herewith submit form PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR §§ 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicants make no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicants make no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Pursuant to 37 CFR § 1.98(d), copies of any patent publication or other information are not required to be provided if they were previously cited by or submitted to the Patent and Trademark Office in a prior application to which priority is claimed under 35 USC §120.

Copies of all items indicated in form PTO 1449 have previously been provided to or cited by the Patent and Trademark Office in prior patent applications Serial No. 10/126,790, filed on April 19, 2002, priority to which has been claimed under 35 USC


§120 for the present application. There are no newly referenced citations in this Information Disclosure Statement.

Applicants respectfully request that the Examiner indicate consideration of the cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

If Examiner in the present application is different from that of the parent application, Applicants request that Examiner consider the prosecution history of said parent application, which may be of interest related to the present application.

As this Information Disclosure Statement is being submitted prior to three months after the filing date of this Application, no fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicants are in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,



Date: October 13, 2003


Brent A. Johnson
Reg. No. 51,851
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4348
Fax: 714-246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on **October 13, 2003** in an envelope as "Express Mail Post Office To Addressee" mailing label number EV295682280US with sufficient postage for Express Mail addressed to Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Susan Bartholomew

Name of person mailing paper



Signature of person mailing paper

Date: October 13, 2003

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17501-CON(AP)	SERIAL NO.: Not yet assigned
APPLICANT: Chang et al	COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE
FILING DATE: Submitted herewith	GROUP: Not yet assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	4,861,760	8/29/1989	Mazuel et al			
	AB	6,248,741B1	6/19/2001	Wheeler et al			
	AC	3,890,319	6/17/1975	Danielewicz et al			
	AD	6,194,415B1	2/27/2001	Wheeler et al			
	AE	5,856,329	1/5/1999	Wheeler et al			
	AF	4,195,085	3/25/1980	Stone			
	AG	6441047 B1	08/2002	Desantes, Jr.			
	AH	6174524 B1	01/2001	Bawa et al.			
	AI	6410045 B1	06/2002	Shultz et al.			
	AJ	6316441 BA	11/2001	Dean et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AG						
	AH						
	AI						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	AJ		"Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy", Stewart et al., Acta Ophthalmologica Scandinavia, 2002, 80(3), 277-281.
	AK		"Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination", Larrson, Lillinger, Archives of Ophthalmology, 2001, 119(4), 492-495.
	AL		"The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma", Yuksel et al., Ophthalmologica, 1999, 213(4), 228-233.
	AM		"A short term study of the additive effect of timolol and brimonidine on intraocular pressure", Arici et al., Eye, 2002, vol. 16, no. 1, pp. 39-43.
	AN		Sall et al., IOVS, 2001k, vol. 42, no. 4, pp. S822.
	AO		"Clinical Experience With Brimonidine 0.2% And Timolol 0.5% In Glaucoma And Ocular Hypertension", Schuman, Survey Of Ophthalmology, 1996, 41 Suppl 1 S27-37.
	AP		"Cardiovascular effects of timolol, brimonidine and brimonidine/timolol in combination", Jackson et al., IOVS, vol. 42, no. 4, pp. S418.
	AQ		"Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination", Larson, IOVS, 1999, vol. 40, no. 4, pp. S515.

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17501 CON (AP)	SERIAL NO.: Not yet assigned
APPLICANT: CHIN-MING CHANG, et al.	TITLE: COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE
FILING DATE: Filed Herewith	GROUP: Not yet assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicabl)
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Hommer, A.B., et al., <i>Efficacy and Safety of Unoprostone, Dorzolamide, and Brimonidine in Adjunctive Therapy to Timolol in Pateitnts with primary open-angle glaucoma and ocular hypertension</i> , Investigative Ophthalmology & Visual Science, Vol. 42, No. 4, Supp. Mar 15, 2001, Pg. 554,
CB	Hoyng, P.F., et al., <i>Pharmacological Therapy of glaucoma</i> , Drugs, Vol. 59, No. 3, March 2000 pgs. 411-434
CC	Larson, L.I., <i>Aqueous humor flow in normal human eyes trated with brimonidine and timolol, alone and in combination</i> , Arch Ophthalmol/ Vol. 119, Apr 2001, pg. 492-495
CD	Schuman, J.S., <i>Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension</i> , Survey of Ophthalmology, Vo. 41, Supp. 1, Noember 1996, pg. s27-s37
CE	Stewart, W.C., <i>Perspectives in the medical treatment of glaucoma</i> , Current Opinion in Ophthalmology, Vol. 10, No. 2, April 1999, pp. 99-109
CF	Wang, R.F., et al., <i>Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes</i> , J. of Glaucoma 9:458-62
CG	Yukse,N., et al., <i>The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma</i> , Ophthalmologica, Vol. 213 (1999), pgs. 228-233.

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.